China Resources Double-Crane Pharmaceutical Co.,Ltd. China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

Rank in Stocks #5375
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its... China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
Share Price
$2.28
Last synced: 2026-11-13
Market Cap
$2.36B
Change (1 day)
-0.79%
Change (1 year)
-14.78%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Trade China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)

Category

Healthcare
Operating Margin for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)
Operating Margin as of November 2026 TTM: 15.31%
According to China Resources Double-Crane Pharmaceutical Co.,Ltd.'s latest financial reports, its current operating margin (TTM) is 15.31%. At the end of 2025 the company had an operating margin of 16.86%.
Operating Margin history for China Resources Double-Crane Pharmaceutical Co.,Ltd. from 2000 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 15.31% -9.19%
2025 16.86% 3.06%
2024 16.36% -1.62%
2023 16.63% 12.14%
2022 14.83% 18.83%
2021 12.48% -13.69%
2020 14.46% 7.43%
2019 13.46% -6.92%
2018 14.46% -12.42%
2017 16.51% 7.07%
2016 15.42% 3.70%
2015 14.87% -8.66%
2014 16.28% 7.60%
2013 15.13% 55.34%
2012 9.74% -4.23%
2011 10.17% -6.61%
2010 10.89% 2.64%
2009 10.61% 16.21%
2008 9.13% 5.67%
2007 8.64% 55.12%
2006 5.57% -5.11%
2005 5.87% 118.22%
2004 2.69% -2.18%
2003 2.75% -51.33%
2002 5.65% -25.36%
2001 7.57% -49.06%
2000 14.86% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
19.69% -98.71%
DE
19.68% -98.71%
DE
13.26% -99.13%
JP
17.08% -98.88%
CH
10.53% -99.31%
IL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin

What is China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin?

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin is 15.31%, as of Nov 2026.

What was China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin in 2025?

In 2025, China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin was 16.86%, compared with 16.36% in 2024.

How has China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin changed since 2020?

From 2020 to 2025, China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin was highest in 2025 (16.86%) and lowest in 2021 (12.48%).

How does China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin compare with similar companies?

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s operating margin (15.31%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with 19.69%.